- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01011972
A Study of Intravenous XMT-1107 in Patients With Advanced Solid Tumors (XMT-1107)
January 29, 2018 updated by: Mersana Therapeutics
A Phase 1 Study of the Safety and Pharmacokinetics of XMT-1107 Administered as an Intravenous Infusion Once Every Three Weeks to Patients With Advanced Solid Tumors
XMT-1107 has been shown in nonclinical studies to slow the growth of tumors.
These effects may result from blocking the growth of new blood vessels that help the tumors survive.
Study Overview
Detailed Description
This is an open-label, ascending-dose study of XMT-1107 administered intravenously over 90 minutes every 21 days (1 cycle).
Blood sampling for PK analyses will be performed immediately prior to dosing and after dosing.
Adverse events will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria (CTC) version 4.0 (CTCAE v4.0)
Study Type
Interventional
Enrollment (Actual)
52
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of MD Greenbaum Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Center (BIDMC)
-
Boston, Massachusetts, United States, 02115
- Dana Farber Cancer Institute (DFCI)
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Sarah Cannon Research Institute (SCRI)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient must have a histological diagnosis of advanced solid tumor and must be refractory to standard therapy or have no effective therapy.
- Measurable or evaluable disease.
- At least 42 days since administration of mitomycin or nitrosoureas and 28 days since any other chemotherapy, investigational agent, and/or radiation therapy.
- Age ≥ 18 years old.
Have the following laboratory values:
- Absolute neutrophil count (ANC) ≥ 1500 cells/mm3
- Platelet count ≥ 100,000 cells/mm3
- Hemoglobin ≥ 9 g/dL
- Serum creatinine ≤ 1.5 mg/dL or calculated creatinine clearance ≥ 60 mL/min (Calculated by Cockroft and Gault method. Creatinine clearance (mL/min) = (140-age) x weight (kg)/72 x (serum creatinine in mg/dL) = ml**/min (**for females, multiply results by 0.85))
- Total bilirubin ≤ 1.5 mg/dL or ≤ upper limit of normal (ULN)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times the institutional upper limit of normal (ULN) or ≤ 5 times ULN of liver metastases are present
- Prothrombin time (PT) and partial thromboplastin time (PTT) ≤ 1.5 times the ULN
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1.
- Life expectancy of at least 3 months.
- Signed informed written consent.
Exclusion Criteria:
- Known brain metastases (either currently or previously).
- Peripheral neuropathy ≥ Grade 2.
- Ataxia ≥ Grade 1.
- Cognitive disturbance ≥ Grade 1.
- History of seizures.
- Patients known to be human immunodeficiency virus (HIV) positive.
- Active infections requiring IV antibiotics or serious intercurrent illness, including hepatitis B or C.
- Unstable angina, recent myocardial infarction (within the previous 6 months), or use of ongoing maintenance therapy for life-threatening arrhythmia.
- Known hypersensitivity to this class of drugs.
- Pregnant or nursing women, women who are of childbearing potential and are not using an effective method of either barrier or hormonal contraceptives. Men who are not using an effective method of barrier contraceptive, or who would not be willing to continue to use these effective methods for the duration of the study.
- Patients who have had a major surgical procedure (not including mediastinoscopy), open biopsy, or significant traumatic injury ≤ 4 weeks prior to beginning treatment.
Patients with proteinuria at screening as demonstrated by either:
- urine protein creatinine (UPC) ratio ≥ 1.0 at screening OR
- urine dipstick for proteinuria ≥ 2+ (patients discovered to have ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection, and must demonstrate ≤ 1 g of protein/24 hours to be eligible)
- Patients with a serious non-healing wound, active ulcer, or untreated bone fracture.
- Patients with history of hematemesis or hemoptysis (defined as having bright red blood of ½ teaspoon or more per episode) ≤ 1 month prior to study enrollment.
- Inadequately controlled hypertension (defined as systolic blood pressure >140 mm Hg and/or diastolic blood pressure > 90 mm Hg while on antihypertensive medications). Initiation of antihypertensive agents is permitted provided adequate control is documented at least 1 week prior to beginning study treatment.
- Significant vascular disease (e.g., aortic aneurysm requiring surgical repair, or recent peripheral arterial thrombosis) ≤ 6 months prior to Day 1 of treatment.
- History of stroke or transient ischemic attack ≤ 6 months prior to beginning treatment.
- Any prior history of hypertensive crisis or hypertensive encephalopathy.
- History of abdominal fistula or gastrointestinal perforation ≤ 6 months prior to Day 1 of beginning treatment.
- QTc interval > 470 milliseconds as calculated by Bazett's formula.
- Any issue that, in the opinion of the Investigator, would render the patient unsuitable for study participation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: XMT-1107
Dose escalation groups of XMT-1107, I.V. (in the arm) beginning at 6 mg/m^2, doubling in dose to 24 mg/m^2, then 40 mg/m^2, then 60 mg/m^2, then 80 mg/m^2 with subsequent doses at 33% of the previous until disease progression or unacceptable side effects are experienced.
|
6 mg XMT-1107 administered by I.V. (in the vein) administered over 90 min, once every 21 days : until progression or unacceptable toxicity develops
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary objective of this study is to determine the maximum tolerated dose of XMT-1107 when given via IV once every three weeks.
Time Frame: Adverse events are assessed during each treatment cycle.
|
Adverse events are assessed during each treatment cycle.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Assess the pharmacokinetics (PK) of XMT-1107 and its release product
Time Frame: Samples for PK are collected during Cycle 1 and prior to each subsequent treatment cycle
|
Samples for PK are collected during Cycle 1 and prior to each subsequent treatment cycle
|
Determine the recommended Phase 2 dose of XMT-1107
Time Frame: Throughout Cycle 1
|
Throughout Cycle 1
|
Assess the safety of XMT-1107.
Time Frame: Throughout Cycle 1
|
Throughout Cycle 1
|
Observe for evidence of anti-tumor activity by XMT-1107.
Time Frame: Course of study
|
Course of study
|
Monitor the effect of XMT-1107 on MetAP2 inhibition in leukocytes from patients
Time Frame: Cycle 1 and Cycle 2
|
Cycle 1 and Cycle 2
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Johana Bendell, MD, Sara Cannon Research Institute
- Principal Investigator: Edward Sausville, MD, University of Maryland, Greenbaum Cancer Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2010
Primary Completion (Actual)
September 1, 2013
Study Completion (Actual)
September 1, 2013
Study Registration Dates
First Submitted
November 10, 2009
First Submitted That Met QC Criteria
November 10, 2009
First Posted (Estimate)
November 11, 2009
Study Record Updates
Last Update Posted (Actual)
January 31, 2018
Last Update Submitted That Met QC Criteria
January 29, 2018
Last Verified
September 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MER-1107-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasm Metastasis
-
Betta Pharmaceuticals Co., Ltd.Recruiting
-
BayerCompleted
-
BayerCompletedNeoplasm Metastasis / Bone and BonesBelgium, Spain, Taiwan, United States, Japan, Russian Federation, Canada, Finland, Korea, Republic of, Singapore, Australia, Germany, Israel, United Kingdom, Italy, France, Poland, Brazil, Czechia, Norway, Sweden, Hong Kong
-
National Cancer Institute (NCI)TerminatedCancer | Neoplasm Metastasis | Metastasis | Neoplasm | Radiation OncologyUnited States
-
MedtronicNeuroCompletedMetastasis Spine | Metastasis to BoneUnited States, Luxembourg, Germany, France, Canada
-
Cho Ray HospitalUniversity of Medicine and Pharmacy at Ho Chi Minh CityRecruitingSynchronous Neoplasm | Liver Metastasis Colon CancerVietnam
-
Li MinRecruiting
-
Da FuGanzhou City People's HospitalRecruiting
-
University of Mississippi Medical CenterCompletedMetastasisUnited States
-
Assiut UniversityNot yet recruiting
Clinical Trials on XMT-1107
-
Mersana TherapeuticsRecruitingHER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2-positive Non-Small Cell Lung Cancer | HER2-positive Colorectal Cancer | HER2-positive Tumors | HER2 Low Breast CancerUnited States
-
Mersana TherapeuticsRecruitingBreast Cancer | Adenoid Cystic Carcinoma | Ovarian Cancer | Fallopian Tube Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Primary Peritoneal Cavity CancerUnited States
-
Mersana TherapeuticsIQVIA BiotechTerminatedOvarian Cancer | Nonsmall Cell Lung CancerUnited States
-
Mersana TherapeuticsIQVIA Biotech; PSI CROTerminatedPlatinum-sensitive Ovarian Cancer (UPGRADE-A)United States
-
Mersana TherapeuticsCompletedAdvanced Breast Cancer | Advanced Gastric Cancer | Advanced Nonsmall Cell Lung CancerUnited States
-
Mersana TherapeuticsIQVIA Biotech; PSI CRORecruitingPlatinum Resistant Ovarian Cancer | Non Small Cell Lung Cancer MetastaticUnited States, Spain, United Kingdom, Australia, France, Austria, Belgium, Bulgaria, Canada, Czechia, Denmark, Finland, Hungary, Italy, Lithuania, New Zealand, Norway, Poland, Sweden
-
Mersana TherapeuticsCompletedSmall Cell Lung Cancer | Non-small Cell Lung CancerUnited States
-
Mersana TherapeuticsGOG Foundation; European Network of Gynaecological Oncological Trial Groups...TerminatedUpifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) (UP-NEXT)Fallopian Tube Cancer | Primary Peritoneal Cancer | High Grade Serous Ovarian CancerUnited States, Australia, Canada